Evaluating the efficacy and immunological impact of combined ICIs and SBRT in HCC: A narrative literature review.

Clin Transl Radiat Oncol · 2026 · PMC12882063 · PMID 41657362

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

[58] , which was terminated early due to slow accrual, the addition of SBRT to nivolumab and ipilimumab showed a trend to improved ORR, PFS and OS compared to Nivolumab alone.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.